PMID-40847331 – GLP-1RA and Colorectal Cancer Risk: Meta-Analysis
Zhong J et al. "Glucagon-like peptide-1 receptor agonists and risk of colorectal cancer: a meta-analysis," BMC Gastroenterology, 2025.
Quick Reference
| Property | Value |
|---|---|
| PMID | 40847331 |
| DOI | — |
| Year | 2025 |
| Journal | BMC Gastroenterology |
| Study Type | Meta-analysis |
| Evidence Level | II |
| Sample | Pooled data from multiple RCTs and observational studies |
| Peptide(s) Studied | Semaglutide, Tirzepatide |
Key Findings
- Pooled relative risk of colorectal cancer (CRC) with GLP-1RA use was RR 2.31, suggesting a potential signal
- However, confounding is likely the dominant factor: GLP-1RA users (T2D/obesity populations) have independently elevated CRC risk due to metabolic syndrome, insulin resistance, and obesity
- When restricted to RCTs only, the signal attenuated substantially
- The absolute number of CRC events was small across included studies
- Authors conclude that the association is likely non-causal and driven by confounding
Study Design
Meta-analysis combining data from randomized controlled trials and observational studies examining the relationship between GLP-1RA use and colorectal cancer incidence. Included subgroup analyses by study type (RCT vs. observational) and GLP-1RA agent.
Limitations
- Mixing RCT and observational data introduces confounding by indication
- GLP-1RA users have metabolic profiles (obesity, T2D, insulin resistance) that independently increase CRC risk
- Small number of CRC events limits statistical power
- Inadequate adjustment for diet, physical activity, and other CRC risk factors in observational studies
- Evidence level downgraded to II due to the observational data component and confounding concerns
Clinical Relevance
While the headline RR of 2.31 appears concerning, this study must be interpreted with extreme caution due to confounding. The GLP-1RA-treated population has inherently elevated CRC risk due to metabolic comorbidities. The larger RCT-only meta-analyses (PMID-41359966, PMID-40437949) do not confirm this signal. This study does not warrant changes to GLP-1RA prescribing but supports standard CRC screening recommendations for metabolically at-risk patients.
Related
#research #meta-analysis #evidence-level-II #cancer